한국형 양극성 장애 약물치료 알고리듬 2022: 우울 삽화
Korean Medication Algorithm Project for Bipolar Disorder 2022: Depressive Episode
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives After the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was developed in 2002, its fifth revision was completed in 2022 to reflect the recent rapid developments and research into bipolar disorder and its psychopharmacology. Methods According to the methodology for previous versions, the depressive episode section of KMAP-BP 2022 was revised based on a survey consisting of 11 questions. Among ninetythree experts, eighty-seven members of the review committee (93.5%) completed the survey. The executive committee analyzed the results and discussed the final production of an algorithm by considering the scientific evidence. Results Overall, the results from this study showed little change in comparison with previous versions of KMAP-BP. However, there have been significant changes in recommendations over the span of about 20 years. The preferences for lamotrigine and atypical antipsychotics, especially aripiprazole, quetiapine, and olanzapine, have shown a tendency to continuously increase, but the preferences for risperidone and ziprasidone have not increased, but have decreased. Moreover, the preference for typical antipsychotics has significantly decreased. Additionally, concerns over the use of antidepressants in bipolar depression have been raised, and their use is not recommended in KMAP-BP 2022 as a first-line treatment. Conclusion Pharmacotherapy for acute depressive episodes with various clinical progressions and various subtypes still shows diversity, compared to pharmacotherapy for mania. We look forward to the development of bipolar depressive, episode-specific therapeutic drugs in the future, and hope the fifth update of KMAP-BP will be a complementary option for clinicians and their patients with bipolar disorder.
Abstract
Objectives After the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was developed in 2002, its fifth revision was completed in 2022 to reflect the recent rapid developments and research into bipolar disorder and its psychopharmacology. Methods According to the methodology for previous versions, the depressive episode section of KMAP-BP 2022 was revised based on a survey consisting of 11 questions. Among ninetythree experts, eighty-seven members of the review committee (93.5%) completed the survey. The executive committee analyzed the results and discussed the final production of an algorithm by considering the scientific evidence. Results Overall, the results from this study showed little change in comparison with previous versions of KMAP-BP. However, there have been significant changes in recommendations over the span of about 20 years. The preferences for lamotrigine and atypical antipsychotics, especially aripiprazole, quetiapine, and olanzapine, have shown a tendency to continuously increase, but the preferences for risperidone and ziprasidone have not increased, but have decreased. Moreover, the preference for typical antipsychotics has significantly decreased. Additionally, concerns over the use of antidepressants in bipolar depression have been raised, and their use is not recommended in KMAP-BP 2022 as a first-line treatment. Conclusion Pharmacotherapy for acute depressive episodes with various clinical progressions and various subtypes still shows diversity, compared to pharmacotherapy for mania. We look forward to the development of bipolar depressive, episode-specific therapeutic drugs in the future, and hope the fifth update of KMAP-BP will be a complementary option for clinicians and their patients with bipolar disorder.
참고문헌 (29)
- Field MJ, "Guidelines for clinical practice: from development to use", pp.26~27 (1992), National Academy Press
- 박원명, "양극성 장애의 한국형 약물치료 알고리듬", 대한정신약물학회지, 13(3), pp.205~221 (2002), 대한정신약물학회
- Jon DI, "Revised Korean medication algorithm for bipolar disorder", World J Biol Psychiatry, 10(4 Pt 3), pp.846~855 (2009)
- 민경준, "한국형 양극성 장애 약물치료 알고리듬 2006(Ⅲ)：우울 삽화", 대한정신약물학회지, 17(5), pp.436~448 (2006), 대한정신약물학회
- Shin YC, "Korean medication algorithm for bipolar disorder : second revision", Asia Pac Psychiatry, 5, pp.301~308 (2013)
- 서정석, "한국형 양극성 장애 약물치료 알고리듬 2010 : 우울 삽화", Mood and Emotion, 9(2), pp.96~102 (2011), 대한우울조울병학회
- Woo YS, "Korean medication algorithm project for bipolar disorder : third revision", Neuropsychiatr Dis Treat, 11, pp.493~506 (2015)
- 서정석, "한국형 양극성 장애 약물치료 알고리듬 2014: 우울 삽화", 대한정신약물학회지, 25(2), pp.68~78 (2014), 대한정신약물학회
- 서정석, "한국형 양극성 장애 약물치료 알고리듬 2018 : 우울 삽화", Mood and Emotion, 16(2), pp.57~68 (2018), 대한우울조울병학회
- Maj M, "The prognostic significance of “switching” in patients with bipolar disorder: a 10-year prospective follow-up study", Am J Psychiatry, 159, pp.1711~1717 (2002)
- Altshuler LL, "Antidepressant-induced mania and cycle acceleration : a controversy revisited", Am J Psychiatry, 152, pp.1130~1138 (1995)
- Quitkin FM, "Prophylactic lithium carbonate with and without imipramine for bipolar 1patients. A double-blind study", Arch Gen Psychiatry, 38, pp.902~907 (1981)
- Goldberg JF, "Suicidal ideation and pharmacotherapy among STEPBD patients", Psychiatr Serv, 56, pp.1534~1540 (2005)
- Yerevanian BI, "Bipolar pharmacotherapy and suicidal behavior: part 2. The impact of antidepressants", J Affect Disord, 103, pp.13~21 (2007)
- Gijsman HJ, "Antidepressants for bipolar depression: a systematic review of randomized, controlled trials", Am J Psychiatry, 161, pp.1537~1547 (2004)
- Altshuler L, "Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up", Am J Psychiatry, 160, pp.1252~1262 (2003)
- Fu AZ, "Second-generation antidepressant discontinuation and depressive relapse in adult patients with bipolar depression : results of a retrospective database analysis", Clin Ther, 28, pp.979~989 (2006)
- Salvi V, "The use of antidepressants in bipolar disorder", J Clin Psychiatry, 69, pp.1307~1318 (2008)
- "Bipolar disorder: the management of bipolar disorder in adults, children, and adolescents, in primary and secondary care. Clinical guideline" (2006)[URL]
- Yatham LN, "Canadian network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
- (2020)[URL]
- Geddes JR, "Lamotrigine for treatment of bipolar depression : independent meta-analysis and meta-regression of individual patient data from five randomised trials", Br J Psychiatry, 194, pp.4~9 (2009)
- Young AH, "A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)", J Clin Psychiatry, 71, pp.150~162 (2010)
- McElroy SL, "A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)", J Clin Psychiatry, 71, pp.163~174 (2010)
- Fountoulakis KN, "Aripiprazole monotherapy in the treatment of bipolar disorder : a meta-analysis", J Affect Disord, 133, pp.361~370 (2011)
- Berman RM, "The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 68, pp.843~853 (2007)
- Perugi G, "The role of electroconvulsive therapy (ECT) in bipolar disorder: effectiveness in 522 patients with bipolar depression, mixed-state, mania and catatonic features", Curr Neuropharmacol, 15, pp.359~371 (2017)
- Leucht C, "Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials", Schizophr Res, 127, pp.83~92 (2011)
- Prajapati AR, "Second-generation antipsychotic long-acting injections in bipolar disorder : systematic review and meta-analysis", Bipolar Disord, 20, pp.687~696 (2018)